Journal ArticleDOI
Coagulation and sepsis
Reads0
Chats0
TLDR
Adjunctive strategies focused at the impairment of coagulation, including anticoagulants and restoration of physiological antICOagulant mechanisms, may supposedly be indicated and have been found advantageous in experimental and initial clinical trials.About:
This article is published in Thrombosis Research.The article was published on 2017-01-01. It has received 465 citations till now. The article focuses on the topics: Coagulation factor II receptor & Disseminated intravascular coagulation.read more
Citations
More filters
Journal ArticleDOI
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.
TL;DR: A relatively high mortality of severe coronavirus disease 2019 (COVID‐19) is worrying, and the application of heparin in CO VID‐19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous thromboembolism, but its efficacy remains to be validated.
Journal ArticleDOI
Extrapulmonary manifestations of COVID-19.
Aakriti Gupta,Aakriti Gupta,Mahesh V. Madhavan,Kartik Sehgal,Kartik Sehgal,Nandini Nair,Shiwani Mahajan,Tejasav S. Sehrawat,Behnood Bikdeli,Behnood Bikdeli,Neha Ahluwalia,John C. Ausiello,Elaine Wan,Daniel E. Freedberg,Ajay J. Kirtane,Sahil A. Parikh,Mathew S. Maurer,Anna S. Nordvig,Domenico Accili,Joan M. Bathon,Sumit Mohan,Kenneth A. Bauer,Kenneth A. Bauer,Martin B. Leon,Harlan M. Krumholz,Nir Uriel,Mandeep R. Mehra,Mitchell S.V. Elkind,Mitchell S.V. Elkind,Gregg W. Stone,Allan Schwartz,David D. Ho,John P. Bilezikian,Donald W. Landry +33 more
TL;DR: The extrapulmonary organ-specific pathophysiology, presentations and management considerations for patients with COVID-19 are reviewed to aid clinicians and scientists in recognizing and monitoring the spectrum of manifestations, and in developing research priorities and therapeutic strategies for all organ systems involved.
Journal ArticleDOI
The immunopathology of sepsis and potential therapeutic targets
TL;DR: Pivotal for the clinical development of new sepsis therapies is the selection of patients on the basis of biomarkers and/or functional defects that provide specific insights into the expression or activity of the therapeutic target.
Journal ArticleDOI
D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19.
TL;DR: Early and effective predictors of clinical outcomes are urgently needed to improve management of Covid‐19 patients, and a global spreading trend is shown.
Journal ArticleDOI
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia
Dennis McGonagle,Dennis McGonagle,James S. O’Donnell,Kassem Sharif,Paul Emery,Paul Emery,Charlie Bridgewood,Charlie Bridgewood +7 more
TL;DR: The immune mechanism underlying diffuse alveolar and pulmonary interstitial inflammation in COVID-19 involves a MAS-like state that triggers extensive immunothrombosis, which might unmask subclinical cardiovascular disease and is distinct from the MAS and disseminated intravascular coagulation that is more familiar to rheumatologists.
References
More filters
Journal ArticleDOI
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.
Derek C. Angus,Walter T. Linde-Zwirble,Jeffrey Lidicker,Gilles Clermont,Joseph A. Carcillo,Michael R. Pinsky +5 more
TL;DR: Severe sepsis is a common, expensive, and frequently fatal condition, with as many deaths annually as those from acute myocardial infarction, and is especially common in the elderly and is likely to increase substantially as the U.S. population ages.
Journal ArticleDOI
The Epidemiology of Sepsis in the United States from 1979 through 2000
TL;DR: The rate of sepsis due to fungal organisms increased by 207 percent, with gram-positive bacteria becoming the predominant pathogens after 1987, and the total in-hospital mortality rate fell, yet the total number of deaths continued to increase.
Journal ArticleDOI
Efficacy and safety of recombinant human activated protein C for severe sepsis.
G Ordon R. B Ernard,J Ean L Ouis V Incent,L Aterre,S Teven P. L A R Osa,J Ean,A Ngel L Opez,J Ay S. S Teingrub,G Ary E. G Arber,J Effrey,D. H Elterbrand,E. W Esley E Ly,C Harles J. F Isher,S Evere S Epsis,S Tudy G Roup +13 more
TL;DR: This phase 3 trial assessed whether treatment with drotrecogin alfa activated reduced the rate of death from any cause among patients with severe sepsis.
Journal ArticleDOI
Thrombin signalling and protease-activated receptors
TL;DR: Roles for PARs are beginning to emerge in haemostasis and thrombosis, inflammation, and perhaps even blood vessel development.
Journal ArticleDOI
Disseminated Intravascular Coagulation
Marcel Levi,Ten Cate H +1 more
TL;DR: Bleeding may be the presenting symptom in a patient with disseminated intravascular coagulation, a factor that can complicate decisions about treatment, and the use and subsequent depletion of platelets and coagulating proteins resulting from the ongoing coagulations may induce severe bleeding.
Related Papers (5)
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Mervyn Singer,Clifford S. Deutschman,Christopher W. Seymour,Manu Shankar-Hari,Djillali Annane,Michael Bauer,Rinaldo Bellomo,Gordon R. Bernard,Jean-Daniel Chiche,Craig M. Coopersmith,Richard S. Hotchkiss,Mitchell M. Levy,John C. Marshall,Greg S. Martin,Steven M. Opal,Gordon D. Rubenfeld,Gordon D. Rubenfeld,Tom van der Poll,Jean Louis Vincent,Derek C. Angus +19 more
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
Clinical Characteristics of Coronavirus Disease 2019 in China.
Wei-jie Guan,Zhengyi Ni,Yu Hu,Wenhua Liang,Chun-Quan Ou,Jianxing He,Lei Liu,Hong Shan,Chunliang Lei,David S.C. Hui,Bin Du,Lanjuan Li,Guang Zeng,Kowk-Yung Yuen,Ruchong Chen,Chun-Li Tang,Tao Wang,Ping-Yan Chen,Jie Xiang,Shiyue Li,Jinlin Wang,Zi-jing Liang,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Nanshan Zhong +36 more